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Abstract
Background: The transforming growth factor (TGF)-β is one of the key mediators in cardiac remodelling occurring
after myocardial infarction (MI) and in hypertensive heart disease. The TGF-β-stimulated clone 22 (TSC-22) is a
leucine zipper protein expressed in many tissues and possessing various transcription-modulating activities.
However, its function in the heart remains unknown.
Methods: The aim of the present study was to characterize cardiac TSC-22 expression in vivo in cardiac remodelling
and in myocytes in vitro. In addition, we used TSC-22 gene transfer in order to examine the effects of TSC-22 on
cardiac gene expression and function.
Results: We found that TSC-22 is rapidly up-regulated by multiple hypertrophic stimuli, and in post-MI remodelling
both TSC-22 mRNA and protein levels were up-regulated (4.1-fold, P <0.001 and 3.0-fold, P <0.05, respectively)
already on day 1. We observed that both losartan and metoprolol treatments reduced left ventricular TSC-22 gene
expression. Finally, TSC-22 overexpression by local intramyocardial adenovirus-mediated gene delivery showed that
TSC-22 appears to have a role in regulating collagen type IIIα1 gene expression in the heart.
Conclusions: These results demonstrate that TSC-22 expression is induced in response to cardiac overload.
Moreover, our data suggests that, by regulating collagen expression in the heart in vivo, TSC-22 could be a
potential target for fibrosis-preventing therapies.
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Background
Various stimuli such as increased mechanical stress,
neurohumoral activation or myocardial injury initiate
pathological alterations in the heart, referred to as car-
diac remodelling [1]. Common features of pathological
cardiac remodelling include alterations in cardiomyocyte
size, modulation of the extracellular matrix (ECM), in-
flammation, and microvascular perturbations [1]. Cardiac
remodelling leads to further deterioration of cardiac func-
tion, and eventually to heart failure, one of the leading
causes of mortality and morbidity worldwide [1, 2].
At molecular level, cardiac remodelling is the result of al-
tered gene expression that is regulated by the activation of
numerous transcription factors including GATA-4, myo-
cyte enhancer factor-2, Nkx2.5, serum response factor and
SMADs [3]. Transcription factors are, in turn, regulated by
several signalling pathways such as mitogen-activated
kinases (MAPKs) p38, extracellular signal-regulated kinase
(ERK) and c-Jun N-terminal kinase (JNK) [4, 5]. One of
the key mediators involved in the pathological remodelling
in cardiac hypertrophy and after myocardial infarction is
the transforming growth factor beta (TGF-beta) [6], which
regulates cardiomyocyte hypertrophy, fibroblast prolifera-
tion, inflammatory response and extracellular matrix
metabolism through direct and indirect mechanisms [7, 8].
TGF-β also regulates several cardiac transcription factors
including Smad 4, Smad 6/7 and cAMP response
element-binding protein (CREB1) [6, 9]. Although it has
been studied extensively, the role of transcriptional regula-
tion of pathological cardiac remodelling is not yet fully
understood.
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TSC-22 (TGF-β stimulated clone 22) is a member of
leucine zipper proteins, first isolated as TGF-β respon-
sive gene form mouse osteoblastic cells [10]. Although
the DNA binding surface of TSC-22 differs from that of
the other basic leucine zipper proteins, it can homodimer-
ize and heterodimerize with other transcription factors
such as SMADs [11–14], and it has transcriptional repres-
sion activity [11]. Several physiological roles for TSC-22
have been identified: TSC-22 is thought to be a tumour
suppressor in several cancer cell lines and tumour tissue
[15–21], regulating developmental processes in Xenopus
laevis during gastrulation and in oogenesis of Drosophila
melanogaster [14, 22], apoptosis [17, 21], and systemic
cholesterol metabolism [23] as well as promoting cardiac
myofibroblast differentiation and fibrosis [13]. TSC-22 is
up-regulated by many stimuli, including different cyto-
kines, fibroblast growth factor 2 (FGF2), and epidermal
growth factor (EGF) [24]. In addition, elevated TSC-22
mRNA-levels have been reported in an experimental
model of essential hypertension, in spontaneously hyper-
tensive rats (SHRs) [25], and after experimental myocar-
dial infarction in rats [26]. Thus, TSC-22 may have an
important role in controlling the transcriptional response
of cardiac remodelling.
Here we assessed TSC-22 expression levels in the heart
and used adenovirus-mediated gene delivery in the normal
rat heart in order to investigate the effects of TSC-22 on
cardiac gene expression and function. In addition, we ana-
lysed the effect of TSC-22 overexpression on hypertrophic
gene response in cultured neonatal rat ventricular myo-
cytes (NRVMs). We demonstrated that multiple hyper-
trophic stimuli and post-MI remodelling regulate TSC-22
expression in the heart. Our data shows that TSC-22 has
a role in regulating collagen Col3a1 gene expression in the
heart in vivo, suggesting it may be involved in the develop-
ment of cardiac ECM remodelling.
Methods
Expression and purification of TSC-22 for antibody
production
For TSC-22 (also known as TSC-22D1) protein pro-
duction, the cDNA coding for rat TSC-22 (GeneBank
accession number L25785) was subcloned into the
NdeI-BamHI site of pET-15b expression vector (Novagen/
Merck, Darmstadt, Germany) containing an amino terminal
(His)6-tag. The construct was transformed into the E. coli
BL21(DE3) cells and grown in LB-medium in the presence
of ampicillin (100 μg/ml) at +37 °C. Protein expression was
induced by 1 mM isopropyl b-D-thiogalactoside (IPTG) for
3 h, after which the cells were harvested, suspended in a
lysis buffer (100 mM NaH2PO4, 10 mM Tris–HCl, 8 M
urea, pH 8.0) and stored at −70 °C. The cells were melted
and sonicated 10 times for 10 s (200–300 V). The soluble
protein fraction was obtained by centrifuging at 10 000 × g
for 30 min at +4 °C.
Recombinant protein containing a His-tag at the amino
terminus was purified on a Ni-NTA-agarose (Qiagen,
Venlo, Netherlands) according to the manufacturer’s
instructions. Briefly, the agarose was stirred with the sol-
uble fraction of the E. coli supernatant for 2 h. The matrix
was washed in the buffer (100 mM NaH2PO4, 10 mM
Tris–HCl, 8 M urea, pH 6.3). Proteins were first eluted
in the buffers containing 100 mM NaH2PO4, 10 mM
Tris–HCl, 8 M urea, pH 5.9 and pH 4.5, respectively and
continued in the buffer containing 100 mM NaH2PO4,
10 mM Tris–HCl, 8 M urea, 250 mM imidazole, pH 3.5.
Eluted proteins were concentrated with a Centricon
Centrifugal Filter device (Millipore, Billerica, MA, USA)
and separated with preparative SDS-PAGE. The gel was
stained by 0.25 mM KCl [27] and TSC-22 was cut from
the gel and eluted in a 3 ml buffer containing 20 mM
Tris–HCl pH 8.0, 0.01 % SDS, 1 mM CaCl2 at +37 °C over-
night, after which the buffer was changed into phosphate-
buffered saline (PBS) by PD-10 column (GE Healthcare,
Little Chalfont, United Kingdom). The antibody against
TSC-22 was produced in rabbits by Davids Biotechnology
(Regensburg, Germany). TSC-22 protein was injected three
different times for immunization, and rabbit serum anti-
body was purified by precipitation and affinity purification.
The specificity of the TSC-22 antibody was tested with the
pure TSC-22 protein used as an antigen.
Animals
Newborn, 2- to 4-day-old Sprague–Dawley rats of both
sexes and male 2- to 3-month-old SD rats weighing
from 250 to 300 g as well as 12-to-20-month-old spon-
taneously hypertensive rats (SHR) of the Okamoto-Aoki
strain and age-matched Wistar-Kyoto (WKY) rats from
the colony of the Centre of Experimental Animals at the
University of Oulu, Finland, were used. The SHR strain
was originally obtained from Møllegaards Avslaborator-
ium, Skensved, Denmark. All rats were kept in plastic
cages with free access to tap water and regular rat chow
in a room with a controlled 40 % humidity and a
temperature of 22 °C. A 12 h light and 12 h dark envir-
onmental light cycle was maintained. All experimental
protocols were approved by the Animal Use and Care
Committee of the University of Oulu and the Provincial
Government of Western Finland Department of Social
Affairs and Health. The study conforms to the Guide for
the Care and Use of Laboratory Animals published by
the US National Institutes of Health.
Experimental design in conscious normotensive and
hypertensive rats
The Sprague Dawley rats were anesthetized with 0.26 mg/
kg fentanyl citrate, 8.25 mg/kg fluanisone and 4.1 mg/kg
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midazolam i.p., and instrumented for vehicle and drug
infusions as previously described [25]. The experiments
were started in conscious animals by measuring mean
arterial pressure (MAP) and heart rate for 30 min be-
fore baseline hemodynamic measurements were made.
Then arginine vasopressin (AVP) (Peninsula Labora-
tories Europe) at a dose of 0.05 mg/kg per minute or
vehicle (0.9 % NaCl) was infused i.v. at 37.5 ml/min
for 30 min and 4 h.
Angiotensin II (Sigma Chemicals) (33 μg/kg/h) or vehicle
(0.9 % NaCl) was administered through subcutaneously
implanted osmotic minipumps (Alzet, Durect Corporation,
Cupertino, CA, USA) in conscious rats for 6, 12 and 72 h,
and 2 weeks as described previously [25]. In a separate
series of experiments, vehicle (0.9 % NaCl), Ang II (33 μg/
kg/h), losartan (400 μg/kg/h) [25] (a generous gift from
Merck), or Ang II in combination with losartan was
administered for 6 h.
In addition, osmotic minipumps (Alzet) releasing meto-
prolol (Sigma-Aldrich, St. Louis, MO, USA) (1.5 mg/kg/h)
or losartan (400 μg/kg/h) were placed subcutaneously in
WKY and SHRs, as described above. At the end of experi-
ments, the rats were decapitated, the thoracic cavity was
opened, and the heart was removed, left ventricular
samples were blotted dry, weighed, frozen in liquid nitro-
gen and stored at −70 °C for further analysis.
Experimental myocardial infarction
Myocardial infarction was produced by ligation of the
left anterior descending coronary artery (LAD) [28]. The
male Sprague–Dawley rats were anesthetized, a left
thoracotomy and pericardial incision was made, and the
LAD was ligated as previously described [29], producing
left ventricular dilation, thinning of the anterior wall and
hypertrophy of the posterior wall [29]. In a separate
series of experiments, osmotic minipumps (Alzet) releas-
ing metoprolol (Sigma-Aldrich) 1.5 mg/kg/h or losartan
(400 μg/kg/h) were placed subcutaneously. The sham
operated rats underwent the same surgical procedure
without osmotic minipumps or ligation of LAD.
Recombinant adenovirus vectors and adenoviral gene
transfer in vivo
The recombinant adenoviruses containing the coding re-
gions of the constitutively active MKK3b (RAdMKK3bE)
and wild-type (WT) p38α (RAdp38α) genes driven by the
cytomegalovirus immediate early promoter were gener-
ated as described [30]. Recombinant replication-deficient
adenovirus RAdlacZ, which contains the Escherichia coli
β-galactosidase (LacZ) gene, was used as a control virus.
The recombinant adenovirus AxCAmTSC-22 (deposited
by Kazunari Yokoyama) and AxCALacZ (deposited by
Izumu Saito) were provided by the DNA Bank, RIKEN
BioResource Center (Tsukuba, Japan) with the support of
National Bio-Resources Project of Ministry of Education,
Culture, Sports, Science and Technology Japan (MEXT).
The recombinant adenovirus harbouring mouse TSC-22
(TGF beta 1-inducible gene) cDNA AxCAmTSC-22
(hereinafter referred to as TSC-22) and AxCALacZ (here-
inafter referred to as LacZ) expressing beta-galactosidase,
used as a control virus, were under the control of a CAG
promoter [31].
Adenovirus-mediated gene transfer into the left ven-
tricle was performed as a local intramyocardial injection,
as previously described [32]. Male Sprague–Dawley rats
weighing 250–300 g were anesthetized with medetomi-
dine hydrochloride (Domitor 250 μg/kg, i.p.) and keta-
mine hydrochloride (Ketamine 50 mg/kg, i.p.). A left
thoracotomy and pericardial incision was made. Recom-
binant TSC-22 adenovirus with a dose of 7 × 109 pfu in a
100-μL volume was injected using a Hamilton precision
syringe directly into the anterior wall of the left ventricle;
the heart was then repositioned in the chest and the
incision was closed. After the operation, the anaesthesia
was partially antagonized with atipamezole hydrochloride
(Antisedan 1.5 mg/kg, i.p.) and the rats were given bupre-
norphine hydrochloride (Temgesic, 0.05-0.2 mg/kg s.c.)
for analgesia.
Echocardiography
Transthoracic echocardiography was performed using
a commercially available Acuson Ultrasound System
(SequoiaTM 512) and a 15-MHz linear transducer
(15 L8) (Acuson, Mountain View, CA, USA) as previ-
ously described [29, 33]. Echocardiographic measure-
ments were performed by a skilled sonographer blinded to
the treatments. After echocardiography, the animals were
sacrificed, their hearts were weighed and the tissue
samples were immersed in liquid nitrogen and stored
at −70 °C for later analysis.
Cell culture
Cell cultures of cardiac ventricular cells were isolated from
2-to-4 day old Sprague–Dawley rats as described [34].
The animals were killed by cervical dislocation and the
ventricles were excised and cut into small pieces, and
thereafter incubated 1–2 h at +37 °C in a solution contain-
ing 100 mM NaCl, 10 mM KCl, 1.2 mM KH2PO4,
4.0 mM MgSO4, 50 mM taurine, 20 mM glucose, 10 mM
Hepes, 2 mg/ml collagenase type 2 (Worthington, Lake-
wood, NJ, USA), 2 mg/ml pancreatin (Sigma-Aldrich, St
Louis, MO, USA) and 1 % penicillin–streptomycin (PS).
The detached cells were collected after incubation by
centrifuging at 900 rpm for 5 min. The bottom layer of
the pellet containing undamaged isolated cardiomyocytes
was plated on 35 mm dishes at a density of 1.4 × 105/cm2.
The cells were cultured overnight in Dulbecco’s modi-
fied Eagle’s medium nutrient mixture F-12 ham with
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L-glutamine (DMEM/F12) containing 10 % foetal bo-
vine serum (FBS) and 1 % PS. Thereafter the cells were
cultured in complete serum free medium (CSFM) con-
taining DMEM/F12, 2.5 mg/ml bovine serum albumin,
1 μM insulin, 5.64 μg/ml transferrin, 32 nM selenium,
2.8 mM Na-pyruvate, 0.1 nM T3 and 1 % PS. The cells
were infected with adenoviruses 24 h after the cells
were plated at the virus concentration of 2, 4 or 8 MOI
(multiplicity of infection). Fresh CSFM was changed
24 h after the infection and cells were cultured in all
72 h before being washed twice with ice-cold PBS and
stored at −70 °C. Endothelin-1 (ET-1) treatment was
performed as described before [35, 36].
Isolation and analysis of RNA
Total RNA from tissue samples was isolated by the
guanidine thiocyanate-CsCl method and from cultured
cardiomyocytes with TRIzol Reagent according to the
manufacturer’s protocol (Invitrogen, CA, USA) by using
the Phase Lock Gel system (Eppendorf AG, Hamburg,
Germany) as previously described [37]. For Northern
Blot analyses, 20 μg samples of RNA from LV tissue
were separated on agarose–formaldehyde gel electro-
phoresis and transferred to nylon membranes (Osmonics
Inc.). PCR-amplified Northern probes corresponding fol-
lowing genes: rat TSC-22 and 18S were random primer-
labelled with [α32P]dCTP, and the membranes were
hybridized and washed as described previously [25]. The
hybridization signals were normalized to 18S RNA quan-
tified from the same samples.
Rat TSC-22, Atrial natriuretic peptide (ANP), B-type
natriuretic peptide (BNP), interleukin-6 (IL-6), connect-
ive tissue growth factor (CTGF), plasminogen activator
inhibitor-1 (PAI-1), fibronectin-1 (Fn-1), collagen type
Iα1 (Col1a1) and type IIIα1 (col3a1), Bcl-2-associated X
protein (Bax2), B-cell lymphoma 2A (Bcl2A) and 18S
mRNA levels were measured by real time quantitative
PCR using TaqMan chemistry on an ABI 7300 Sequence
Detection System (Applied Biosystems, Foster City, CA,
USA) as described previously [37]. The sequences of the
forward and reverse primers and fluorogenic probes for
RNA are given in Table 1. The results were normalized
to 18S RNA quantified from the same samples.
Protein extraction
The tissue was broken in liquid nitrogen, and homoge-
nized in a lysis buffer consisting of 20 mmol/L Tris
(pH 7.5), 10 mmol/L NaCl, 0.1 mmol/L EDTA, 0.1 mmol/
L EGTA, 1 mmol/L β-glycerophosphate, 1 mmol/L
Na3VO4, 2 mmol/L benzamidine, 1 mmol/L PMSF,
50 mmol/L NaF, 1 mmol/L DTT and 10 μg/mL of each
leupeptin, pepstatin and aprotinin as previously described
[32, 37]. The tissue homogenates were centrifuged at
2000 rpm in +4 °C for 1 min. To separate the total protein
fraction, 5× NEB was added to the tissue homogenate,
following by centrifugation at 12,500 rpm for 20 min. The
supernatant was stored in −70 °C until assayed.
To extract total protein from cultured cardiomyocytes,
the cells were scraped in 100–150 μl of 1× NEB buffer
containing protease-inhibitor cocktail (1:100 volume),
phosphatase-inhibitor cocktail (1:100 volume) and 1 mM
dithiothreitol (DTT) (1:1000 volume). Cells were vortexed
for 20 s and centrifuged 12,500 rpm for 20 min at +4 °C.
The supernatant was collected as the total protein frag-
ment. The entire procedure was carried out at +4 °C. The
supernatant was stored in −70 °C until assayed. Protein
concentrations were determined by colorimetric assay
(Bio-Rad Laboratories, Hercules, CA, USA).
Western blotting
Western blots were performed as previously described
[35]. Briefly, 15–60 μg of protein was loaded onto a
Table 1 Sequences of primers and fluorogenic probes used in
real time quantitative RT-qPCR analysis (sequences 5′ to 3′)
Gene Forward Primer Reverse Primer Fluorogenic Probe
TSC-22 GCAGGAGAACAATC TGCAGCTGGG CCAGTCCGGAG
TGTTGAAGAC CCTGAAAC CAGCTCGCC
ANP GAAAAGCAAACTG CCTACCCCCG TCGCTGGCCCT
AGGGCTCTG AAGCAGCT CGGAGCCT
BNP TGGGCAGAAGATAG ACAACCTCAG CGGCGCAGTCA
ACCGGA CCCGTCACAG GTCGCTTGG
IL-6 ATATGTTCTCAGGG TGCATCATCGC CAGAATTGCCATTGCA
AGATCTTGGAA TGTTCATACAA CAACTCTTTTCTCA
CTGF CGCCAACCGCAAGA CACGGACCCA CACTGCCAAAGA
TTG CCGAAGAC TGGTGCACCCTG
PAI-1 GCTGACCACAGCAG GTGCCCCTCTCA CCCGGCAGCAGAT
GGAAA CTGATATTGAA CCAAGATGCTAT
col1a1 CCCCTTGGTCTTGG GCACGGAAAC CTTTGCTTCCCAGATGT
AGGAA TCCAGCTGAT CCTATGGCTATGATG
Fn-1 GCGAGGCAGGATC CCAATCTTGTA ACCATTGCAAAT
AGCTG GGACTGACCCC CGCTGCCATGAA
Bax2 TCCCCCCGAGAGG CCCAGTTGAAG CCGGGTGGCAGCT
TCTTCT TTGCCATCA GACATGTTTG
Bcl2A GGAACTATATGG AGGCTGAGCA CGACCTCTGTTTG
CCCCAGCAT GGGTCTTCAG ATTTCTCCTGGCTGTC
col3a1 AGCTGGCCTTCCTC GCTGTTTTTGCAG TTCCAGCCGG
AGACTTC TGGTATGTAATG GCCTCCCAG
18S TGGTTGCAAAGCT AGTCAAATTA CCTGGTGGTGC
GAAACTTAAAG AGCCGCAGGC CCTTCCGTCA
TSC-22 transforming growth factor beta-stimulated clone 22; ANP atrial
natriuretic peptide; BNP B-type natriuretic peptide; IL-6 interleukin-6; CTGF
connective tissue growth factor; PAI-1 plasminogen activator inhibitor-1; col1a1
collagen type Iα1; Fn-1 fibronectin-1; Bax2 Bcl-2-associated X protein; Bcl2A
B-cell lymphoma 2A; col3a1 collagen type IIIα1
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SDS-PAGE gel and transferred to nitrocellulose filters.
The membranes were blocked in 5 % non-fat milk and in-
cubated with anti-TSC-22 polyclonal antibody (dilution
1:500 in 0.5 % milk-TBS-Tween) overnight. After incuba-
tion with secondary anti-rabbit antibody (Cell Signaling
Technology, Danvers, MA, USA) at the dilution of 1:2000,
the protein amount was detected by ECL Plus (GE Health-
care Life Sciences). For Odyssey detection, the membranes
were blocked in Odyssey Blocking Buffer – TBS (1:1) and
incubated with anti-TSC-22 polyclonal antibody or
anti-GAPDH (glyceraldehyde-3-phosphate dehydrogen-
ase) (Millipore, MA, USA) overnight. After incubation
with secondary Alexa Fluor anti-rabbit or anti-mouse
antibody (Invitrogen), the protein levels were detected
using Odyssey Infrared Detection.
Histological analysis
For immunohistochemical analysis, the hearts were fixed
in 10 % buffered formalin solution. Transverse sections
of the left ventricle were embedded in paraffin, and 5-
μm-thick sections were cut from the midsection of the
heart, at the level of the papillary muscles. Sections were
deparaffinised in xylene and dehydrated in graded etha-
nol, and to identify cellular localization of TSC-22, incu-
bated with specific anti-TSC-22 polyclonal antibody at a
dilution of 1:500. The primary antibody was detected by a
peroxidase conjugated Dako REAL™ EnVision™ Detection
System, Peroxidase/DAB kit (Dako, Glostrup, Denmark)
according to the manufacturer’s instructions, and the sam-
ples were counterstained with hematoxylin and eosin. All
measurements were performed by persons blinded to the
treatments.
Human LV tissue samples
LV samples were obtained from explanted human hearts
from 4 patients with cardiomyopathy (2 dilated, 1 idio-
pathic, 1 hypertrophic) undergoing heart transplantation.
Non-diseased donor hearts unsuitable for transplant
were used to obtain control myocardial tissue (n = 2). All
tissues were obtained with signed informed consent of
the subjects. The project was approved by the local Eth-
ics Committee (Ethical permission number: 5012-0/
2011-EKU142/PI/11–Semmelweis University, Hungary)
and conducted in accordance with the guidelines of the
Declaration of Helsinki.
Statistics
Statistical analysis was performed by unpaired Student’s
t-test or One-way Analysis of variance (ANOVA)
followed by a least significant difference (LSD) post hoc
test for multiple comparisons. A value of P <0.05 was
considered to be statistically significant. The results are
expressed as mean ± standard error of the mean (SEM).
Results
Cardiac remodelling in chronic hypertension and after
experimental myocardial infarction modulates TSC-22
gene expression
DNA-microarray studies have previously shown that
TSC-22 mRNA levels are elevated both in old SHRs [33]
and after experimental MI in rats [26]. First, we exam-
ined TSC-22 protein levels, which were higher in 12-to-
20-month-old SHR (1.6-fold, P <0.05) compared with
age-matched normotensive WKY rats (Fig. 1a). Then we
investigated the induction of TSC-22 in the heart more
carefully after MI. Similarly to gene expression profiles of
Stanton et al. [26], LV TSC-22 mRNA levels were up-
regulated 4 weeks after MI (Fig. 1b). In addition, a signifi-
cant increase in mRNA levels was seen already on day 1
following MI when compared to sham-operated animals
(4.1-fold, P <0.001), indicating that TSC-22 induction in
the post-infarction cardiac remodelling process is rapid
and persistent. Similar profiles to mRNA, in the degree
and the time course of the induction, were seen in the
protein up-regulation, as assessed by Western blot analysis
(Fig. 1c). TSC-22 mRNA and proteins were also found to
be expressed in the left ventricle of control human hearts
and in patients with cardiomyopathy, but there were no
changes in the expression levels between failing and
control hearts (data not shown).
TSC-22 gene expression is induced in the adult heart with
acute pressure overload
Next, we studied the effect of acute and chronic pressure
overload on LV TSC-22 expression. Ang II increased
TSC-22 mRNA levels from 6 h to 2 weeks, the greatest
increase (12.0-fold, P <0.001) being observed after 6 h of
Ang II infusion (Fig. 2a). Accordingly, in vivo administra-
tion of AVP induced a small, but significant increase in
TSC-22 already after 1 h, and at 4 h, TSC-22 mRNA levels
were markedly elevated (5.5-fold, P <0.001) (Fig. 2b).
Moreover, the Ang II type 1-receptor antagonist losartan
completely abolished the changes in TSC-22 gene expres-
sion induced by Ang II in the left ventricle (Fig. 2c).
The effect of long-term treatment of heart failure with
metoprolol and hypertension with metoprolol or losartan
on TSC-22 expression
Next, we aimed to characterize whether TSC-22 expres-
sion changes in response to a treatment with a beta-
blocker metoprolol or losartan in left ventricular hyper-
trophy or heart failure. First, we characterized the LV
TSC-22 gene expression in rats treated with metoprolol
during the remodelling in post-MI [38]. Post-infarction
treatment with metoprolol improved LV systolic and dia-
stolic function and attenuated LV remodelling as previ-
ously described [38]. After MI, LV TSC-22 mRNA levels
were increased 2.8-fold (P < 0.001) (Fig. 3a). Metoprolol
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administration for 2 weeks via osmotic minipumps re-
duced LV TSC-22 mRNA levels by 32 % (P <0.05). Next,
we infused metoprolol for two weeks in 12-month-old
SHRs. Metoprolol treatment lowered the heart beat and
reduced enlargement of LV end-diastolic dimension
(7.7 ± 0.1 in SHR vs. 8.5 ± 0.1 in SHR treated with
metoprolol; P <0.001). Again, metoprolol reduced
significantly the TSC-22 mRNA levels in metoprolol-
treated SHRs when compared with untreated SHRs
(Fig. 3b). A similar decrease in TSC-22 gene expression
was also seen after 2 weeks of losartan infusion in SHRs
(Fig. 3b), when reduced thickness of the LV wall was
seen in losartan-treated SHRs compared to untreated
SHRs (interventricular septal thickness −15.4 %,
P<0.001 and left ventricular posterior wall thickness in
diastole −18.2 %, P <0.05).
Signalling pathways regulating TSC-22 gene expression
We determined the cellular mechanisms involved in the
regulation of TSC-22 gene expression by testing the ef-
fect of hypertrophic agonist ET-1 on TSC-22 mRNA
levels in neonatal rat ventricular myocytes (NRVMs).
ET-1 (100 nM) significantly increased TSC-22 gene
expression with maximal mRNA levels at 12 h (2.7–fold,
P <0.001) (Fig. 4a) and protein levels at 24 h (4.7-fold,
P<0.001) (Fig. 4b). Next, we investigated intracellular
signalling pathways mediating ET-1 induced TSC-22
gene expression by focusing on MAPKs, since all MAPK
pathways are key signalling routes known to be activated
in the heart in response to hypertrophic stimuli including
ET-1 [4]. The neonatal rat ventricular myocytes were ex-
posed to kinase inhibitors SB203580 (10 μM) or PD98059
(10 μM), and the cells were treated with 100 nM ET-1 for
1 h. Neither PD98059 (Fig. 4c) nor SB203580 (Fig. 4d) had
significant effect on ET-1 –induced increase in TSC-22
mRNA levels in NRVMs. However, the p38α and p38β
MAPK inhibitor SB203580 significantly increased TSC-22
mRNA levels in NRVMs (Fig. 4d).
Finally, in order to determine whether p38 MAPKs
regulate cardiac TSC-22 gene expression in vivo, adeno-
viruses expressing constitutively active MKK3bE and
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Fig. 1 Effects of cardiac remodelling on chronic hypertension and,
after experimental myocardial infarction (MI), on transforming growth
factor beta-stimulated clone 22 (TSC-22) expression. a Left ventricular
(LV) tissue TSC-22 total protein levels were analysed by Western blot
from 12 and 20 months old Wistar Kyoto (WKY) and spontaneously
hypertensive rat (SHR) hearts (n = 5). Open bars represent WKY and
solid bars SHR *P<0.05 versus WKY (Student’s t-test). The effect of MI
on LV tissue TSC-22 mRNA levels (b) measured by Northern blot or
RT-PCR and TSC-22 protein levels (c) analysed by Western blot
(n = 6−8). Open bars represent sham and solid bars MI *P<0.05,
**P <0.01, ***P <0.001 versus sham (Student’s t-test). The results are
expressed as mean ± SEM. Representative Western blots are shown
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WT p38alpha to cause p38 MAPK-overexpression were
injected into the LV free wall of adult Sprague–Dawley
rats. Adenoviral p38 MAPK overexpression significantly
increased both TSC-22 mRNA (1.8-fold, P <0.01) and
protein levels (4.1-fold, P <0.01) at day 3 following gene
transfer (Fig. 4e-f).
The role of TSC-22 in regulating cardiac gene expression
In order to study the direct myocardial effects of TSC-
22 in regulating cardiac gene expression, we established
an in vivo gene transfer protocol to locally increase
TSC-22 levels in the adult rat heart. First, the efficiency
and functionality of the adenovirus gene transfer was
A
B
C
Fig. 2 The effect of acute and chronic pressure overload on
transforming growth factor beta-stimulated clone 22 (TSC-22) gene
expression. a The effect of angiotensin II (Ang II) administration
(33 μg/kg/h) on left ventricular (LV) TSC-22 mRNA levels assessed by
Northern blot analysis in rats (n = 6−8). Open bars represent control
and black bars Ang II ***P <0.001 versus control (Student’s t-test).
b TSC-22 mRNA levels after arginine vasopressin (AVP) infusion
(n = 9). Open bars represent control and solid bars AVP *P <0.05,
***P <0.001 versus control (Student’s t-test). c The effect of Ang II
and AT1-receptor antagonist losartan (Los) on LV TSC-22 mRNA
levels at 6 h (n = 5−8). *P <0.05, ***P <0.001 versus control.
ƗƗƗP <0.001 versus Ang II (one-way ANOVA followed by least
significance difference post hoc test). The results are expressed
as mean ± SEM. Representative Northern blots are shown
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Fig. 3 The effect of long-term treatment of heart failure and
hypertension with metoprolol on transforming growth factor
beta-stimulated clone 22 (TSC-22) expression. a Left ventricular
(LV) TSC-22 mRNA levels measured by RT-PCR from rats 2 weeks
after myocardial infarction (MI) and after metoprolol (METO)
treatment post-MI (n = 7-8). ***P <0.001 versus sham. ƗP <0.001
versus MI (one-way ANOVA followed by least significance difference
post hoc test). b LV TSC-22 mRNA levels from 12-month-old Wistar
Kyoto (WKY) rats, untreated spontaneously hypertensive rats (SHR)
and SHRs treated with metoprolol (METO) or losartan (Los) for 14 days
(n = 5-6). *P <0.05 versus untreated SHR (one-way ANOVA followed by
least significance difference post hoc test). The results are expressed
as mean ± SEM
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studied by transducing the cardiomyocyte cell cultures
with TSC-22 adenovirus. Adenovirus transduction mark-
edly increased both TSC-22 mRNA and protein levels at
the virus amounts of 2, 4 and 8 MOI in a dose-dependent
manner (Fig. 5a, b).
Next, the effect of TSC-22 gene delivery on cardiac func-
tion was studied in vivo [32]. TSC-22 mRNA levels were in-
creased in response to adenoviral TSC-22 overexpression at
three days up to 2 weeks (7.7-fold, P <0.001 and 1.7-fold,
P<0.01, respectively) following injections (Fig. 6a). Similarly,
the induction in TSC-22 protein levels was seen 3 days after
TSC-22 gene transfer (Fig. 6b). TSC-22 gene transfer had
no significant effect on LV dimensions or cardiac function
as assessed by echocardiography (Table 2).
To evaluate the localization of TSC-22, we performed
immunohistochemical studies of TSC-22 overexpressing
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Fig. 4 Signalling pathways regulating transforming growth factor beta-stimulated clone 22 (TSC-22) gene expression. Cultured neonatal rat ventricular
myocytes (NRVMs) were treated with endothelin-1 (ET, 100 nM) for 1, 4, 12 and 24 h. a TSC-22 mRNA levels were measured by RT-PCR (n= 9−12 from
three independent experiments) b) and TSC-22 total protein levels were determined by Western blot (n = 4). Open bars represent control and solid
bars ET **P <0.01, ***P <0.001 versus control (one-way ANOVA followed by least significance difference post hoc test). TSC-22 mRNA levels in NRVMs
exposed to kinase inhibitor (c) PD98059 (10 μM) or d) SB203580 (10 μM), and treated with 100 nM ET for 1 h (n = 8−9, from three independent
experiments). **P <0.01, ***P <0.001 versus control (Student’s t-test). TSC-22 e) mRNA levels measured by Northern blot and f) total protein levels analysed
by Western blot in left ventricle (LV) of Sprague–Dawley (SD)-rats after adenovirus induced MKK3bE and WT p38alpha overexpression at day 3 (n= 7–10).
Open bars represent LacZ and solid bars MKK3bE and WT p38alpha **P<0.01 versus LacZ (Student’s t-test). The results are expressed as mean ± SEM.
Representative Western blots are shown
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hearts and LacZ injected control hearts. At 3 days,
TSC-22 immunohistochemistry showed a very strong
cytoplasmic staining that localized to the endothe-
lium of myocardial capillaries at the injection site
(Fig. 6c). In addition, some myocytes in the inflam-
mation area of TSC-22 overexpressing hearts dis-
played cytoplasmic and nuclear positivity in TSC-22
immunostaining. In control hearts, there was also
some positivity in the myocytes of inflammation
areas, but this was weaker than in TSC-22 overex-
pressing hearts, and no remarkable endothelial posi-
tivity could be seen.
Next, we determined the influence of TSC-22 gene
transfer on expression of several well-established markers
of cardiac hypertrophy, fibrosis and apoptosis. TSC-22
gene delivery did not have an influence on expression
levels of natriuretic peptides (ANP and BNP), inflam-
matory and ECM modulatory factors (IL-6, CTGF,
PAI-1, Fn-1, col1a1) or apoptosis (Bax2, Bcl2A). The
only statistically significant difference between the
TSC-22 and LacZ-treated groups was in increased
col3a1 gene expression levels 2 weeks after TSC-22
gene delivery (Fig. 6d).
Discussion
TGF-β is one of the key mediators both in the embryonic
development of the heart and a number of cardiac dis-
eases such as post-MI remodelling and pressure overload
hypertrophy [7, 8]. TGF-β activates transcription factors
such as SMAD proteins, and TSC-22. TSC-22 is suggested
to have functions in controlling tumorigenesis, apoptosis,
cholesterol homeostasis, cardiac fibrosis as well as devel-
opment and differentiation processes [14–23]. Overall in
this study, we extended knowledge of the role of TSC-22
in the heart. We found that TSC-22 gene expression is
rapidly up-regulated by multiple hypertrophic stimuli and
post-MI remodelling in the heart. We showed that both
losartan and metoprolol treatments reduced left ven-
tricular TSC-22 gene expression levels. We also ob-
served that growth-promoting factor ET-1, activated
TSC-22 mRNA and protein expression in cultured neo-
natal ventricular myocytes, and that p38MAPK signal-
ling regulated cardiac TSC-22 expression in vivo. By
using local intramyocardial adenovirus-mediated gene
delivery, we evaluated the effect of TSC-22 overexpres-
sion on cardiac gene expression, showing that TSC-22
appears to have a role in regulating col3a1 gene expres-
sion in the heart.
In the present study, we showed that TSC-22 gene
expression was rapidly up-regulated in response to AVP-
and Ang II-infused pressure overload, mimicking the
expression patterns of immediate-early genes such as
Egr-1, c-jun and c-fos in response to hemodynamic stress
[39]. Elevated mRNA levels have previously been de-
scribed by chronic pressure overload in the left ventricle
of 20-month-old SHRs and at 2 to 16 weeks after experi-
mental myocardial infarction in the rat [26, 33].
Altogether, the data implies that TSC-22 is up-regulated
throughout the time course of cardiac remodelling sug-
gesting it has a constitutive role in activating cardiac
remodelling-related gene expression. However, although
TSC-22 was expressed in the human heart both at
mRNA and protein level, it was not up-regulated in pa-
tients with end-stage heart failure. Even though we can-
not rule out the species difference (human vs. rodent),
one possibility is that elevated amounts of TSC-22 are
needed for controlling the transcriptional response of
the active remodelling process and in the functional de-
terioration but no longer at the failing stage.
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Fig. 5 Effects of transforming growth factor beta-stimulated clone 22
(TSC-22) overexpression in cultured neonatal rat ventricular myocytes
(NRVMs). TSC-22 a) mRNA levels measured by RT-PCR (n = 8–12) or
b) total protein levels determined by Western blot analysis (n = 4)
from cultured NRVMs transduced with TSC-22 or LacZ adenovirus
for 48 h at the virus amount of 2 MOI, 4 MOI and 8 MOI. **P <0.01,
***P <0.001 versus LacZ (Student’s t-test). The results are expressed
as mean ± SEM. Representative Western blots are shown
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Cardiac remodelling after myocardial infarction and in
hypertensive hypertrophy is an important target for drug
treatment. In our study, both beta-blocker and ATR-
antagonist treatment reduced left ventricular TSC-22
gene expression levels. Several studies suggest that there
is an association between TGF-β1 and both the renin-
angiotensin-aldosterone and the beta-adrenergic systems
[7, 8, 40]. Ang II induces TGF-β1 expression in cardiac
myocytes and fibroblasts in vitro [7, 8, 40]. TGF-β1 is
implicated in AngII-induced cardiac hypertrophy and
beta-adrenergic signalling in the heart in vivo [41–43].
Furthermore, TGF-β1 has been shown to modulate beta-
adrenergic receptors in various cell types [8, 44]. How-
ever, in TGF-β1 transgenic mice chronic β-adrenoceptor
blockade was able to reverse the structural and func-
tional changes of the heart, but treatment with the AT1-
receptor antagonist losartan was not [45]. In our study,
using the rat chronic pressure overload model, both
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Fig. 6 Effects of adenovirus-mediated transforming growth factor beta-stimulated clone 22 (TSC-22) gene delivery in normal rat hearts. TSC-22
a mRNA levels measured by RT-PCR 3 days or 2 weeks (n = 5–8) and b total protein levels analysed by Western blot (n = 8) 3 days after gene delivery
in left ventricular (LV) tissue samples of Sprague–Dawley (SD)-rat hearts. c Localization of TSC-22 at cellular level was studied by immunohistochemical
staining against TSC-22 at day 3 after gene transfer. d mRNA levels of B-type natriuretic peptide (BNP), atrial natriuretic peptide (ANP), interleukin-6
(IL-6), connective tissue growth factor (CTGF), collagen type Iα1 (col1a1), fibronectin-1 (Fn-1), plasminogen activator inhibitor-1 (PAI-1), Bcl-2-associated
X protein (Bax2), B-cell lymphoma 2A (Bcl2A) and collagen type IIIα1(col3a1) measured by RT-PCR from LV of SD-rat hearts 2 weeks after
gene delivery (n = 5). *P <0.05, **P <0.01, ***P <0.001 versus LacZ (Student’s t-test). The results are expressed as mean ± SEM. Representative
Western blots are shown
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betablocker metoprolol and AT1R antagonist losartan
caused a reduction of TSC-22 gene expression, which
could be due to the beneficial effects of these drugs on
the development of cardiac fibrosis [46–48]. In SHR
ventricular remodelling, cardiac hypertrophy is associ-
ated with an increase in fibrosis [49, 50], and it has been
shown that endogenous AngII, mediated by AT1 recep-
tors, plays a role in the formation of fibrosis e.g. by
stimulating of TGF-β1-synthesis [7, 8, 40]. The effect of
the AT1 receptor antagonist on TSC-22 gene expression
was also observed in response to acute pressure over-
load, which can also be due to the inhibition of an Ang
II-induced increase in blood pressure. So, it is likely that
the effects of losartan on TSC-22 expression are ex-
plained by multiple mechanisms.
Almost nothing is known about the mechanisms and
signalling pathways that regulate cardiac TSC-22 gene
expression. We observed that ET-1 activated TSC-22
mRNA and protein expression in cultured neonatal
ventricular myocytes. In our study, no ERK inhibitor
PD98059 or p38 inhibitor SB203580 had an effect on
ET-1-mediated activation of TSC-22 gene expression in
cardiac myocytes. In fact, SB203580 alone was able to
increase TSC-22 levels significantly. In addition, the role
of p38 MAPK as a regulator of TSC-22 expression was
studied in the adult heart in vivo. Since adenovirus-
mediated overexpression of p38 MAPK in vivo increased
TSC-22 gene expression, our results suggest that cardiac
remodelling after MI and in hypertensive hypertrophy
upregulates TSC-22 expression in the heart via the p38
MAPK pathway. However, the results are difficult to inter-
pret because the p38 inhibitor SB203580 did not alter ET-1
induced TSC-22 up-regulation in vitro, which might be
due to the fact that SB203580 by itself at the dose used in
cell culture was able to increase TSC-22 gene expression.
Although expression information alone is not sufficient to
establish firm functional associations, the increased expres-
sion in the p38 MAPK overexpressed hearts exhibiting fi-
brosis and infiltration of inflammatory cells [32] supports
previous findings that the TSC-22 may contribute to the
development of cardiac fibrosis [13].
A key finding of our present study is that TSC-22 gene
delivery in the adult rat heart regulates collagen synthesis.
TSC-22 overexpression in vivo increased col3a1 gene ex-
pression significantly, and there was a similar trend in
col1a1 mRNA levels. In previous studies, lentivirus-
mediated overexpression of TSC-22 enhanced the TGFβ
-induced expression of a- collagen I in cultured rat fibro-
blasts [13] and in kidney cells, TSC-22 was shown to regu-
late col1a2 [51]. Collagens type I and III are major
constituents of cardiac ECM [52], and in fibrosis e.g. the
synthesis of collagen and degradation of collagen scaf-
fold are altered. Our data together with previous find-
ings [13, 51] suggest that TSC-22 has a role in regulating
collagen synthesis during cardiac remodelling. Contrary to
a previous study using neonatal rat cardiac fibroblasts
[13], TSC-22 overexpression did not have any effect on
PAI-1 or fibronectin, which may due to the cell type spe-
cific differences in the regulation of gene expression. Simi-
larly to a previous study [53], TSC-22 was located in both
nuclear and cytoplasmic regions, indicating that TSC-22
might have an effect on cardiac structure by regulating
ECM-modulating genes at transcriptional level.
To summarize, we studied the TSC-22 expression dur-
ing cardiac modelling in post-MI and hypertensive hyper-
trophy. We noticed that TSC-22 expression is rapidly
increased in response to pressure overload and myocardial
injury, and elevated expression levels are sustained until
the failing phase of heart failure. Our analysis provides
new insights into the transcriptional regulation of cardiac
remodelling by showing that TSC-22 appears to have a
role in regulating collagen 3a1 expression in the heart in
vivo. In accordance with previous findings, our data sug-
gests that TSC-22 could be a target for preventing the for-
mation of cardiac fibrosis.
Table 2 Effect of intramyocardial TSC-22 gene delivery on
cardiac function in the normal adult rat heart
Variable Group TSC-22 TSC-22
3 days 2 weeks
Interventricular septum diastole (mm) LacZ 1.9 ± 0.1 2.0 ± 0.1
TSC-22 2.1 ± 0.1 2.0 ± 0.1
Interventricular septum systole (mm) LacZ 2.6 ± 0.1 2.5 ± 0.2
TSC-22 2.7 ± 0.2 2.8 ± 0.2
Left ventricle diastole (mm) LacZ 7.6 ± 0.3 8.6 ± 0.1
TSC-22 7.2 ± 0.3 8.7 ± 0.2
Left ventricle systole (mm) LacZ 5.1 ± 0.3 6.1 ± 0.3
TSC-22 4.7 ± 0.3 6.1 ± 0.3
Posterior wall distole (mm) LacZ 2.3 ± 0.2 1.6 ± 0.1
TSC-22 2.0 ± 0.3 1.5 ± 0.1
Posterior wall systole (mm) LacZ 2.1 ± 0.2 2.3 ± 0.2
TSC-22 2.1 ± 0.1 2.3 ± 0.1
Ejection fraction (%) LacZ 66.7 ± 2.3 58.2 ± 4.5
TSC-22 69.1 ± 3.0 62.8 ± 3.0
Fractional shortening (%) LacZ 32.8 ± 1.7 27.4 ± 2.7
TSC-22 34.7 ± 2.5 30.3 ± 2.0
IVRT LacZ no data 24.8 ± 2.2
TSC-22 no data 25.0 ± 1.6
E/A-ratio LacZ no data 5.1 ± 0.8
TSC-22 no data 2.7 ± 0.6*
n = 7–8 n = 5
Adenoviral gene construct expressing TSC-22 or LacZ were injected into LV
free wall and echocardiographic measurements were performed at 3 days
and 2 weeks after gene transfer. The results are expressed as mean ± SEM.
*P < 0.05 versus LacZ (Student’s t-test). IVRT, isovolumic relaxation time
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Conclusions
In conclusion, TSC-22 expression in the rat heart is regu-
lated by multiple hypertrophic stimuli and post-MI re-
modelling. Our data suggests that TSC-22 might regulate
collagen synthesis in the heart in vivo and could be a
potential target for fibrosis-preventing therapies.
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